2019-nCoV Recombinant Protein
CAT#: TP727640
Recombinant 2019-nCoV Papain-Like Protease
Need it in bulk or customized? Get a free quote |
CNY 3,140.00
货期*
2周
规格
Product images
Specifications
Product Data | |
Species | 2019-nCoV |
Protein Source | E. coli |
Expression cDNA Clone or AA Sequence |
Glu1564-Lys1878
|
Buffer | Supplied as a 0.2 um filtered solution of 20mM Tris-Hcl, 10 mM 2-Mercaptoethanol, 20%glycerol, pH 7.5. |
Note | Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed. |
Storage | Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles. |
Stability | 12 months from date of despatch |
Reference Data | |
Synonyms | Papain-like Protease; PLpro; PL-PRO; pp1a; Replicase polyprotein 1a |
Summary | Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NSP3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons. |
Documents
FAQs |
SDS |
Customer
Reviews
Loading...